Accumulating evidence implicates the gut microbiome (GMB) in the pathogenesis and progression of Alzheimer’s disease (AD). We recently showed that the GMB regulates reactive astrocytosis and Aβ plaque accumulation in a male APPPS1-21 AD mouse model. Yet, the mechanism(s) by which GMB perturbation alters reactive astrocytosis in a manner that reduces Aβ deposition remain unknown. Here, we performed metabolomics on plasma from mice treated with antibiotics (ABX) and identified a significant increase in plasma propionate, a gut-derived short-chain fatty acid, only in male mice. Administration of sodium propionate reduced reactive astrocytosis and Aβ plaques in APPPS1-21 mice, phenocopying the ABX-induced phenotype. Astrocyte-specific RNA-Seq on ABX- and propionate-treated mice showed reduced expression of proinflammatory and increased expression of neurotrophic genes. Next, we performed flow cytometry experiments, in which we found that ABX and propionate decreased peripheral RAR-related orphan receptor-γ + (Rorγt + ) CD4 + (Th17) cells and IL-17 secretion, which positively correlated with reactive astrocytosis. Last, using an IL-17 mAb to deplete IL-17, we found that propionate reduced reactive astrocytosis and Aβ plaques in an IL-17–dependent manner. Together, these results suggest that gut-derived propionate regulates reactive astrocytosis and Aβ amyloidosis by decreasing peripheral Th17 cells and IL-17 release. Thus, propionate treatment or strategies boosting propionate production may represent novel therapeutic strategies for the treatment of AD.
Neuropathic pain after peripheral nerve injury is a multifactorial condition mediated partly by inflammation in the spinal cord that results in potentiation of excitatory synaptic transmission in nociceptive circuits. Glial cells including astrocytes are key mediators of the underlying inflammation, but the signaling checkpoints that regulate astrocyte-driven spinal cord inflammation and sensitization of nociceptive circuits are not well understood. Here, we identify Orai1-mediated store-operated Ca 2+ entry (SOCE) as an important regulator of spinal astrocyte cytokine production, metabolic reprogramming, and pain hypersensitivity in mice. Conditional deletion of Orai1 in astrocytes attenuated mechanical allodynia after nerve injury in male but not female mice, despite comparable SOCE suppression in both sexes. Orai1 deficiency also attenuated production of proinflammatory cytokines after SOCE activation, including TNFα, IL-6, and IL-33, both in vivo and in vitro. Electrophysiological recordings revealed that astrocyte Orai1 deletion prevented injury-induced enhancement of glutamatergic synaptic transmission in dorsal horn neurons, linking astrocytic Ca 2+ signaling to central sensitization. Metabolomic profiling showed that Orai1 loss disrupted glycolysis and TCA cycle intermediates while promoting accumulation of immunomodulatory metabolites such as itaconate, consistent with a less inflammatory astrocyte metabolic state. These findings identify Orai1 channels as integrators of astrocyte Ca 2+ signaling, immunometabolism, and excitatory synaptic potentiation after nerve injury, and identify a sexually dimorphic astrocyte mechanism governing neuropathic pain pathogenesis. Targeting astrocyte Orai1 channels may provide a selective therapeutic strategy for male-predominant chronic pain.